S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Another Bump Up for Dendreon and PROVENGE (DNDN)

Photo of Jon C. Ogg
By Jon C. Ogg Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Dendreon Corporation (NASDAQ: DNDN) is surging on news that the Centers for Medicare and Medicaid Services will now cover the infusion costs associated with the administration of PROVENGE.  Dendreon noted that this new coverage of PROVENGE is now consistent with all other infused biologics.

The costs associated with administering PROVENGE will now be covered and can be billed separately. More importantly, the CMS decision will retroactively cover claims for costs associated with the administration of PROVENGE effective for dates on or after June 30, 2011.  This now takes the average time to pay physicians to 30 days according to the company.

Dendreon shares are up over 8% at $9.03 in pre-market trading with about 55 minutes until the market opens and the 52-week trading range is $6.46 to $43.96.

JON C. OGG

Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. a673b.bigscoots-temp.com.

Continue Reading

David J. Phillips |

Dendreon: Not Running Out Of Cash

In the last four months, Dendreon Corp. (DNDN) has shed almost 84 percent in market value as disgruntled investors washed…
Jon C. Ogg |

The Questionable Dendreon Buyout Incentive

Jon OggDendreon Corp. (NASDAQ: DNDN) is by almost all measurements nothing short of a total failure of a biotech or…
Douglas A. McIntyre |

Will The E.U. Save Dendreon If The U.S. Won’t? (DNDN)

Dendreon Corp. (NASDAQ:DNDN) shares are trading up in early trading on a patent award, and that is after the fairly…
Jon C. Ogg |

Dendreon Shows Poor Provenge Sales, Implosion Risk Rising

ThinkstockDendreon Corp. (NASDAQ: DNDN) just cannot catch a break. Despite having what was supposed to be one of the best…
Jon C. Ogg |

Will the Last Interested Person in Dendreon Turn Out the Lights?

Dendreon is getting crushed, and the share price is down to levels not seen in a decade. The company's reported…
Douglas A. McIntyre |

Dendreon’s New Double-Twist

Dendreon (DNDN-NASDAQ) has an interesting twist this morning because of two issues.  Yesterday it announced some new study data on…
Jon C. Ogg |

Dendreon Restructuring Aims to Thwart Weak Provenge Sales

ThinkstockDendreon Corp. (NASDAQ: DNDN) has been down and out, and now the company is going to try a restructuring strategy…
Jon C. Ogg |

Picking Apart the Dendreon Implosion (DNDN)

Dendreon Corporation (NASDAQ: DNDN) was supposed to be the Holy Grail when it comes to investing in a treatment for…
Jon C. Ogg |

Dendreon Raising $125 Million Via I.P. Sale (DNDN, MRK)

AuthorDendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment.  Unfortunately, PROVENGE sales…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618